Advaxis Inc. (ADXS) Soars 11.44% on January 31

Advaxis Inc. (ADXS) Soars 11.44% on January 31

Advaxis Inc. (ADXS) had a good day on the market for Thursday January 31 as shares jumped 11.44% to close at $0.38. About 603,323 shares traded hands on 1,241 trades for the day, compared with an average daily volume of n/a shares out of a total float of 69.7 million. After opening the trading day at $0.34, shares of Advaxis Inc. stayed within a range of $0.38 to $0.34.

With today’s gains, Advaxis Inc. now has a market cap of $26.42 million. Shares of Advaxis Inc. have been trading within a range of $3.08 and $0.18 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.

Advaxis Inc is a clinical stage biotechnology company operating in the United States. It focuses on discovery, development, and commercialization of proprietary Lm (Listeria monocytogenes)-LLO (Listeriolysin O) cancer immunotherapies. These immunotherapies are based on a platform technology which utilizes live attenuated Listeria monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion proteins. The company’s immunotherapy products based on Lm-LLO immunotherapy are Axalimogene filolisbac (AXAL) which targets Human Papilloma Virus (HPV) – associated cancers and ADXS-PSA which targets Prostate Specific Antigen (PSA) associated with prostate cancer.

Advaxis Inc. is based out of Princeton, NJ and has some 108 employees. Its CEO is Kenneth A. Berlin.

Scroll Up
error: Content is protected !!